1911	Establishment of Lavipharm
1976	A. Lavidas takes helm with new management team
1977	Collaboration with L'Oreal -first to sell cosmetics through pharmacies
1979	Construction of plant for drugs & cosmetics' production
1985	Establishment of R&D department focused on drug delivery
1989	Establishment of Laboratoires Lavipharm in Paris
1992	Joint Ventures with Synthelabo-France (Synthelabo-Lavipharm) and L'Oreal Cosmetique Active (Lavicosmetica)
1993	Completion of transdermal production unit
1995	Launch of nitroglycerine transdermal patch in Italy and France
	Quoted on the Athens Stock Exchange
1996	Establishment of Lavipharm Labs Inc. - USA
1997	Launch of patented acne epidermal patch in Europe by L'Oreal
2000	Acquisition of all outstanding equity of Separex (France) and EKEPY (Greece), also exclusive and perpetual rights to Phasex (USA) and a thirty percent equity stake
2001	Establishment of Lavipharm Pharmaceutical Services Ltd. and its subsidiaries, Lavipharm Distribution Ltd. and Lavipharm Cyprus Ltd. (Cyprus).
2002	Launch of patented epidermal anti-wrinkle patch especially developed for eye contour in Japan Strategic collaboration with GlaxoSmithKline regarding the physical distribution of its pharmaceutical products in Greece
2003	Agreement with the American company Senetek in the pharmaceutical technology area Collaboration agreement between Lavipharm Corp. and GlaxoSmithKline in the Pharmaceutical research area
2004	Acquisition of all outstanding equity of LAS Establishment of Castalia Laboratoires Dermatologiques Lavipharm's dynamic entry in China with Castalia Soins Dermocosmetiques brand Completion of the development of transdermal fentanyl system in the pain management sector by Lavipharm Laboratories Inc. and file of ANDA file at FDA
2005	File for the transdermal fentanyl system in the pain management sector in relevant European authorities Collaboration agreement between Lavipharm and the Italian pharmaceutical company Recordati for the promotion and market of the new transdermal fentanyl system in Italy, Germany, France, Spain and Great Britain.
2006	FDA approval to Lavipharm's generic Fentanyl Transdermal System to market in the United States.
2007	National Organization for Medicine approval to Lavipharm's generic Fentanyl Transdermal System to market in Greece, under the brand name "Fentadur". Lavipharm's Fentanyl patch received approval to market in Germany.